ALAVERT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ALAVERT (ALAVERT).
Loratadine is a selective inverse agonist of peripheral histamine H1 receptors, preventing histamine-mediated effects in allergic reactions.
| Metabolism | Primarily metabolized by CYP3A4 and CYP2D6 to active metabolite descarboethoxyloratadine. |
| Excretion | Approximately 40% of the dose is excreted in urine (25% as unchanged drug and 15% as active metabolite desloratadine) and 40% in feces (as metabolites). |
| Half-life | Terminal elimination half-life of loratadine is 8–11 hours; its active metabolite desloratadine has a half-life of 17–24 hours. The longer half-life of desloratadine contributes to sustained antihistaminic effect. |
| Protein binding | Loratadine: 97–99% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein). Desloratadine: 82–87% bound. |
| Volume of Distribution | Loratadine: approximately 120 L (1.7 L/kg for a 70 kg adult), indicating extensive tissue distribution. Desloratadine: 30–40 L/kg. |
| Bioavailability | Oral bioavailability is low (approximately 40–50%) due to extensive first-pass metabolism. Food increases bioavailability by 40% but does not affect clinical efficacy. |
| Onset of Action | Oral: 1–2 hours for inhibition of histamine-induced wheal and flare. |
| Duration of Action | 24 hours; supports once-daily dosing. Clinical effect persists beyond 24 hours due to active metabolite. |
10 mg orally once daily; for PRN use, 10 mg orally every 4-6 hours as needed, not to exceed 24 mg/day.
| Dosage form | TABLET, ORALLY DISINTEGRATING |
| Renal impairment | For GFR 30-50 mL/min: 10 mg every 48 hours. For GFR <30 mL/min or on dialysis: avoid use or adjust to 10 mg every 72 hours with close monitoring. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: 10 mg every 48 hours. Child-Pugh C: avoid use or 10 mg every 72 hours. |
| Pediatric use | Age 6-11 years: 5 mg orally once daily; for PRN use, 5 mg every 4-6 hours, max 15 mg/day. Age ≥12 years: 10 mg orally once daily or 10 mg every 4-6 hours PRN, max 24 mg/day. |
| Geriatric use | Initiate at 5 mg orally once daily; may increase to 10 mg once daily if tolerated and needed. Caution due to increased risk of anticholinergic effects and impaired renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ALAVERT (ALAVERT).
| Breastfeeding | Loratadine is excreted into human breast milk. The milk-to-plasma ratio is approximately 1.17, with low relative infant dose (<2% of maternal weight-adjusted dose). Considered compatible with breastfeeding, but monitor infant for drowsiness or irritability. Caution in premature infants or those with renal impairment. |
| Teratogenic Risk | ALAVERT (loratadine) is FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects, but no adequate, well-controlled studies in pregnant women. Based on available human data, first trimester exposure does not show increased risk of major malformations. Second and third trimester risks are not established, but adverse fetal outcomes are unlikely given lack of placental transfer concerns. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to loratadine or any component of the formulation"]
| Precautions | ["Avoid use in patients with severe hepatic impairment","Renal impairment may require dose adjustment","Caution in elderly patients due to increased anticholinergic sensitivity"] |
| Food/Dietary | Grapefruit juice may slightly increase loratadine absorption but not clinically significant. No specific dietary restrictions. Alcohol may increase CNS depression. |
| Clinical Pearls |
Loading safety data…
| Fetal Monitoring | Routine prenatal care is sufficient. No specific fetal monitoring required for loratadine use. Monitor maternal blood pressure in patients with preeclampsia risk. |
| Fertility Effects | Loratadine has not been reported to affect human fertility. Animal studies show no impairment of fertility at doses up to 24 mg/kg/day (approximately 190 times the maximum recommended human dose on mg/m^2 basis). |
| Alavert (loratadine) is a non-sedating antihistamine with minimal anticholinergic effects. Onset of action is within 1-3 hours; peak effect at 8-12 hours. Useful for chronic urticaria and allergic rhinitis. Does not cause significant QTc prolongation. Avoid in severe hepatic impairment (Child-Pugh C) without dose adjustment. |
| Patient Advice | Take once daily at the same time, with or without food. · Do not exceed recommended dose to avoid side effects. · May cause mild drowsiness in some patients; avoid driving if affected. · Do not use for acute asthma attacks or lower respiratory symptoms. · Store at room temperature away from moisture and heat. · Notify your doctor if symptoms persist or worsen. |